why choose us

First received: November 15, 2022

Clinical Trial: Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cytomegalovirus Infections

Study Type: INTERVENTIONAL


Official Title: A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

Brief Summary: This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.

Read more